Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Precision Measurement of Neutrino Oscillation Parameters with 10 Years of Data from the NOvA Experiment.

Physical review letters·2026

Same author

Dual-Baseline Search for Active-to-Sterile Neutrino Oscillations in NOvA.

Physical review letters·2025

Same author

Studies on the significance of secretory IgA antibodies in the pathogenesis and clinical course of enterobiasis in infected persons from Bulgaria: preliminary findings.

Helminthologia·2025

Same author

Search for CP-Violating Neutrino Nonstandard Interactions with the NOvA Experiment.

Physical review letters·2024

Same author

INFLAMMATORY FACTORS IN DISSECTION OF THORACIC AORTIC ANEURYSM.

Georgian medical news·2024

Same author

Comparison of Preimplantation Mouse Embryos with Different Genetic Backgrounds as Models for Evaluating Human Embryo Culture Media Composition.

Reproductive sciences (Thousand Oaks, Calif.)·2024

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report.

R Tomova¹, K Antonov, A Ivanova

¹Clinic of Gastroenterology, St Ivan Rilski University Hospital, Ivan Geshov Bvd 15, Sofia, Postal Code 1431, Bulgaria. raditomova@yahoo.com

Anticancer Research

|January 2, 2010

Summary

Interleukin-2 (IL-2) immunotherapy showed promise in a patient with co-infection of hepatitis C (HCV) and B (HBV), leading to undetectable viral loads. This suggests IL-2 may be a novel therapeutic option for chronic viral infections.

More Related Videos

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Related Experiment Videos

Last Updated: Jun 17, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Area of Science:

Immunotherapy
Hepatology
Virology

Background:

Hepatitis C (HCV) and B (HBV) co-infection presents treatment challenges and increases hepatocellular carcinoma risk.
Interleukin-2 (IL-2) has demonstrated antineoplastic and potential antiviral effects, but its role in chronic viral infections is under-researched.

Observation:

A case study involved a 44-year-old patient with hemophilia A and HBV/HCV-related liver cirrhosis (Child-Pugh A), suspected of having hepatocellular carcinoma.
The patient received low-dose, intermittent subcutaneous IL-2 immunotherapy for ten months, followed by standard antiviral therapy.

Findings:

Following IL-2 treatment, HBV DNA and HCV RNA became undetectable within three months.
While a slight viral reactivation occurred after IL-2 cessation and subsequent standard therapy, the patient remained clinically stable with no tumor progression over 23 months.

Implications:

The observed reduction in HBV and HCV viral loads suggests IL-2 immunotherapy could be a potential new therapeutic strategy.
Further research into IL-2's efficacy for chronic viral hepatitis co-infections is warranted.